Omics · study · 2026
Pre-treatment intrinsic T cell features and immune milieu characteristics shape response to Blinatumomab in patients with B-cell Precursor Acute Lymphoblastic Leukemia
Listed in NCBI GEO
Blinatumomab (Blina), a CD19×CD3 bispecific T cell engager, is approved for the treatment of relapsed/refractory and measurable residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL), yet many patients do not respond.
Description
The immune determinants of treatment failure remain poorly understood. We profiled peripheral blood T cells and the immune milieu of 34 patients with BCP-ALL receiving Blina using flow cytometry (n=19), single-cell CITE-seq (n=13), and ex vivo Blina-induced cytotoxicity (n=26) and serum proteomics (n=17).
Patients with overt disease who achieved complete remission, or those with MRD who achieved MRD-negativity after the first cycle, were considered responders (R), the remainder were classified as non-responders (NR). At baseline, R had higher frequencies of CD8⁺ effector memory T cells (TEMs; median 18.6 vs 10.9%, p=0.047) and Granzyme K⁺CD8⁺TEMs (8.8 vs 5.1%, p=0.048). Compared to NR, CD8⁺TEMs from R expressed higher levels of cytotoxic genes and ZNF683, but less CXCR4.
Read the rest (2 more)
Longitudinally, NR exhibited expansion of TIM3⁺CD8⁺ T cells (time×response β=1.91, p=0.025) and impaired T cell function. The Blina-induced peak of TIM3⁺CD8⁺ T cells correlated positively with baseline CXCR4 (r=0.88, p=0.03) and inversely with ZNF683 (r=–0.89, p=0.03) expression in CD8+TEMs. Non-responders exhibited higher circulating levels of immunosuppressive proteins, including CSF-1, ICOSLG, and Galectin-9, throughout the first treatment cycle.
To our knowledge, this is the largest study to determine factors of treatment resistance to blinatumomab. A pre-existing immunosuppressive milieu and subsequent treatment-induced T-cell exhaustion are associated with treatment failure and might serve as biomarkers for risk stratification as well as potential targets to enhance Blina efficacy in BCP-ALL.
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE314nnn/GSE314616 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314616 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1392212 ncbi.nlm.nih.gov/bioproject/PRJNA1392212 ↗
project · from NCBI GEO
- PubMed 42694115 pubmed.ncbi.nlm.nih.gov/42694115 ↗
publication · from NCBI GEO
Topics
- Stated by source
- Expression profiling by high throughput sequencing · Homo sapiens · Other
- From keywords
- Life Sciences
- Inferred from text
- Disease 75% · Mass spectrometry 65%
Provenance · 1 source records, 10 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE314616 | 14 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[disease].local:disease:disease | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencing | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[method].geo_series_type:other | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[modality].local:modality:mass-spectrometry | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (65%) |
| concepts[organism].NCBITaxon:9606 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |